Skip to content
Menu

NuCana plc NCNA

Full chart Compare
Set alert

Price alert · NCNA

All alert types
0.72 USD -0.11 (-13.77%)

Regular-session close

0.73 +0.02 +2.34%

After hours · Nov 19, 7:34 PM ET

0.639 Day range 0.8798
0.639 52-week range 4.55
YTD
-80.05%
1 year
-78.56%

5D -0.0790 (-8.66%)

0.80000.85000.90000.9500ThuFriMonTueWed0.8328
Market cap
2.99M
Shares out
3.93M
Forward P/E
-0.13
YTD return
-80.05%
1-year return
-78.56%
50-day average
1.50
200-day average
3.56
Enterprise value
59.40M
Volume
110.98K
Avg volume
116.56K
Open
0.858
Previous close
0.8328
Day's range
0.639 – 0.8798
52-week range
0.639 – 4.55
Beta
1.04
Price target
64.50 (+8882.0%)

Key statistics

Price / book
0.17
Free cash flow
-7.63M
Total cash
11.64M
Total debt
281.00K
Return on equity
-180.77%

Fundamental scorecard

5 of 25 checks passed on NCNA’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 1 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend No data

Statements to Sep 30, 2026.

Financials — quick view

All financials
NCNA Revenue — quarterly 0
NCNA Net income — quarterly -1.61M
NCNA EPS — quarterly 0.00

Upgrades / downgrades

NCNA analyst upgrades and downgrades
DateFirmActionFromTo
Aug 19, 2024OppenheimerreitOutperformOutperform
Jul 23, 2024OppenheimerreitOutperformOutperform
Jul 22, 2024OppenheimermainOutperformOutperform
Apr 1, 2024OppenheimerreitOutperformOutperform
Nov 21, 2023OppenheimerreitOutperformOutperform
Sep 6, 2023Truist SecuritiesreitBuyBuy

About NuCana plc

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Sector
Healthcare
Industry
Biotechnology
Country
United Kingdom
Website
nucana.com

News

Your note

Sign in to keep a note on NCNA — it syncs with the Stock Master app.

Institution ownership

NCNA institution ownership
Holder% heldSharesValueReported
Carlyle Group Inc.5.04%133,333161.33KSep 29, 2024
Baillie Gifford and Company1.39%36,70444.41KSep 29, 2024
Acadian Asset Management. LLC0.89%23,62428.59KSep 29, 2024
Renaissance Technologies, LLC0.64%16,81820.35KSep 29, 2024
Glass Jacobson Investment Advisors LLC0.57%15,00018.15KSep 29, 2024
UBS Group AG0.48%12,60415.25KSep 29, 2024

Fund ownership

NCNA fund ownership
Holder% heldSharesValueReported
Fidelity NASDAQ Composite Index Fund0.03%751908Oct 30, 2024